ThromboGenics says U.S. authorities clear its main drug
Home page > News

ThromboGenics says U.S. authorities clear its main drug

www.reuters.com   | 18.10.2012.

BRUSSELS (Reuters) - Belgian biotech company ThromboGenics said on Thursday that U.S. health regulators had approved the use of its main drug, eye treatment Jetrea.
br />

The company said the U.S. Food and Drug Administration had cleared use of the drug, also known as ocriplasmin, for treatment of symptomatic vitreomacular adhesion, a pulling on the retina that can cause loss or distortion of vision.

ThromboGenics plans to launch Jetrea in the United States in January 2013.

(Reporting By Philip Blenkinsop)


Comments (0) Add Your comment Add news < Previous news Next news >






  Add your news >>>